- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03294538
Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Cream USP, 0.01% (Teva Pharmaceuticals, USA) to Estrace® Estradiol Vaginal Cream, USP, 0.01% (Warner Chilcott) in the Treatment of Atrophic Vaginitis
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85710
- Site Number 44
-
Tucson, Arizona, United States, 85712
- Site Number 17
-
-
California
-
La Mesa, California, United States, 91942
- Site Number 31
-
Sacramento, California, United States, 95821
- Site Number 11
-
San Diego, California, United States, 91208
- Site Number 05
-
San Diego, California, United States, 92111
- Site Number 15
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80923
- Site Number 25
-
Denver, Colorado, United States, 80209
- Site Number 01
-
Denver, Colorado, United States, 80220
- Site Number 14
-
-
Connecticut
-
New London, Connecticut, United States, 06320
- Site Number 18
-
-
Florida
-
Jupiter, Florida, United States, 33458
- Site Number 06
-
Lake Worth, Florida, United States, 33461
- Site Number 13
-
Miami, Florida, United States, 33015
- Site Number 27
-
Miami, Florida, United States, 33130
- Site Number 40
-
Miami, Florida, United States, 33136
- Site Number 20
-
Miami, Florida, United States, 33144
- Site Number 39
-
Miami, Florida, United States, 33186
- Site Number 38
-
Miami Lakes, Florida, United States, 33014
- Site Number 30
-
New Port Richey, Florida, United States, 34652
- Site Number 08
-
Ormond Beach, Florida, United States, 32174
- Site Number 03
-
Port Saint Lucie, Florida, United States, 34952
- Site Number 45
-
Saint Petersburg, Florida, United States, 33709
- Site Number 19
-
Sarasota, Florida, United States, 34239
- Site Number 10
-
West Palm Beach, Florida, United States, 33409
- Site Number 02
-
-
Georgia
-
Roswell, Georgia, United States, 30075
- Site Number 29
-
Savannah, Georgia, United States, 31406
- Site Number 22
-
-
Kansas
-
Wichita, Kansas, United States, 67226
- Site Number 21
-
-
Louisiana
-
Metairie, Louisiana, United States, 70001
- Site Number 33
-
-
Michigan
-
Kalamazoo, Michigan, United States, 49009
- Site Number 16
-
Saginaw, Michigan, United States, 48604
- Site Number 34
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Site Number 35
-
-
New Jersey
-
Lawrenceville, New Jersey, United States, 08648
- Site Number 12
-
Plainsboro, New Jersey, United States, 08536
- Site Number 26
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- Site Number 36
-
Winston-Salem, North Carolina, United States, 27103
- Site Number 04
-
Winston-Salem, North Carolina, United States, 27103
- Site Number 37
-
-
Ohio
-
Columbus, Ohio, United States, 43213
- Site Number 07
-
Englewood, Ohio, United States, 45322
- Site Number 24
-
West Chester, Ohio, United States, 45069
- Site Number 28
-
-
South Carolina
-
Bluffton, South Carolina, United States, 29910
- Site Number 23
-
Mount Pleasant, South Carolina, United States, 29464
- Site Number 41
-
Myrtle Beach, South Carolina, United States, 29572
- Site Number 43
-
-
Texas
-
Dallas, Texas, United States, 75230
- Site Number 32
-
-
Washington
-
Seattle, Washington, United States, 98105
- Site Number 09
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Informed Consent Form (ICF) that meets all criteria of current Food and Drug Administration (FDA) regulations.
- Females aged 30-75 years inclusive who are postmenopausal, defined as follows:
- At least 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) level of >40 milli-international units per milliliter (mIU/mL); at least 6 weeks post-surgical bilateral oophorectomy, with or without hysterectomy; or hysterectomy without oophorectomy if of age that the Investigator believes would have been naturally reached 12 months of spontaneous amenorrhea.
- Vaginal pH >5.0.
At least 1 of the following participant self-assessed moderate to severe symptoms of vulvar and vaginal atrophy (VVA) from the following list that is identified by the participant as being most bothersome to her:
- Vaginal Dryness
- Vaginal and/or vulvar irritation/itching
- Dysuria
- Vaginal pain or bleeding associated with sexual activity, provided that participant is currently sexually active and plans to remain so throughout study.
- "Normal" Screening mammogram completed within 9 months prior to Screening in all participants >40 years old.
- Normal clinical breast examination at the Screening Visit.
- Documented papanicolaou (PAP) smear conducted within the previous 12 months with no findings that the Investigator believes would contraindicate the use of topical vaginal estradiol.
- Participants with an intact uterus should have vaginal ultrasonography results to confirm an inactive endometrial lining, defined as endometrial thickness less than 4 millimeters (mm).
Exclusion Criteria:
- Females younger than 30 years of age or older than 75 years of age.
- Participants with a Serum follicle-stimulating hormone (FSH) level of ≤40 mIU/mL at Screening.
- Greater than 5% superficial cells on vaginal cytology.
- Vaginal pH ≤5.
- Significant history or current evidence of chronic infectious disease, system disorder, organ disorder (including significant liver/kidney impairment) or other medical condition that in the Investigator's opinion would place the study participant at undue risk by participation or could jeopardize the integrity of the study evaluations.
- Participants with an intact uterus should have vaginal ultrasonography results to confirm an inactive endometrial lining. Participants with an endometrial thickness equal to or greater than 4 mm.
- Documented PAP smear conducted within the previous 12 months with findings that the Investigator believes would contraindicate the use of topical vaginal estradiol.
Participants with known concurrent vaginal infections including but not limited to:
Candida albicans, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhea, or Gardnerella vaginalis.
- Participants with active vaginal herpes simplex infection or have had an outbreak within 30 days of the first dosing day.
- Participants with known, suspected, or current history of carcinoma of the breast. All participants over the age of 40 must have had a mammogram performed within 9 months of the study start and all participants will have a physical breast exam performed at Screening.
- Participants with known, suspected or current history of hormone dependent tumor.
- Participants with baseline systolic blood pressure of >150 millimetres of mercury (mmHg) and/or diastolic pressure >90 mmHg.
- Any participant with undiagnosed vaginal bleeding or significant risk factors for endometrial cancer.
- Any history of estrogen-dependent neoplasia (for example, endometrial cancer).
- History of acute thrombophlebitis or thromboembolic disorder.
- Any current or recent (within the previous 6 months) genital bleeding of unknown etiology.
- Any prescription treatment or over-the-counter (OTC) or natural remedies for vaginal dryness/irritation within 28 days of Screening. Products used for lubrication during sexual intercourse within 7 days of Screening.
- Participants whose fasting triglyceride levels are greater than 350 mg/dL.
- Any participant with a history of radiation therapy or recent (within previous 6 weeks) surgical therapy to the vaginal or cervical areas.
- Any known or suspected allergies that in the Investigator's opinion would compromise the safety of the participant.
- Participants who have used vaginal hormonal products (rings, creams, gels) within the 28 days prior to Screening.
- Any participant who has used transdermal estrogen and/or progestin therapy within the 28 days prior to Screening.
- Participants who have used oral estrogen and/ or progestin therapy or intrauterine progestin therapy within the 56 days prior to Screening.
- Participants who have used progestin implants or estrogen alone injectable drug therapy within the 3 months before Screening.
- Participants who have used estrogen pellet therapy or progestin injectable drug therapy within the 6 months before Screening.
- Participants who, in the opinion of the Investigator, would be non-compliant with the requirements of the study protocol.
- Participants who are unable or unwilling to give informed consent.
- Receipt of any drug as part of a research study within 30 days prior to Screening.
- Participants who have participated in this study previously.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Generic Estradiol Vaginal Cream USP, 0.01%
Participants were to self-administer 2 grams (g) of generic Estradiol Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
|
Vaginal cream, generic formulation of the brand product.
|
Active Comparator: Estrace Vaginal Cream USP, 0.01%
Participants were to self-administer 2 g of Estrace Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
|
Vaginal cream, brand product.
|
Placebo Comparator: Vehicle Vaginal Cream
Participants were to self-administer 2 g of vehicle vaginal cream once daily at approximately the same time of the day for 7 consecutive days.
|
Vaginal cream, placebo.
Has no active ingredient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Identified as a Responder After Completing Study Treatment in the Generic Estradiol Vaginal Cream and Estrace Vaginal Cream Groups
Time Frame: Up to Day 9
|
Treatment comparison of the number of participants in the PP population that were identified as responders at the end of the treatment period evaluated on Day 8 + 1 is presented.
A responder was defined as a participant with at least a 25% reduction from baseline in the sum of percent basal/parabasal + percent intermediate cells on vaginal cytology and vaginal pH ≤5.0 with a change from baseline vaginal pH of at least 0.5.
Any participant who withdrew from the study because of lack of efficacy was included as a non-responder.
|
Up to Day 9
|
Number of Participants Identified as a Responder After Completing Study Treatment in the Generic Estradiol Vaginal Cream, Estrace Vaginal Cream, and Vehicle Vaginal Cream Groups
Time Frame: Up to Day 9
|
Treatment comparison of the number of participants in the mITT population that were identified as responders at the end of the treatment period evaluated on Day 8 + 1 is presented.
A responder was defined as a participant with at least a 25% reduction from baseline in the sum of percent basal/parabasal + percent intermediate cells on vaginal cytology and vaginal pH ≤5.0 with a change from baseline vaginal pH of at least 0.5.
|
Up to Day 9
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Identified as Treatment Success After Completing Study Treatment in the Generic Estradiol Vaginal Cream and Estrace Vaginal Cream Groups
Time Frame: Up to Day 9
|
The number of participants in the PP population that are identified as Treatment Success at the end of the treatment period evaluated on Day 8 ± 1 is presented.
A Treatment Success is defined as a score of 0 or 1 at Day 8 ± 1 for the symptom identified at baseline as the most bothersome.
This evaluation was based on participant self-assessed symptoms of vulvar and vaginal atrophy on a scale of 0 to 3 where 0 = none and 3 = severe.
The symptoms that were evaluated were vaginal dryness, vaginal/vulvar irritation/itching, dysuria, vaginal pain associated with sexual activity, and vaginal bleeding.
Any participant who withdrew from the study because of lack of efficacy was included as a non-responder.
|
Up to Day 9
|
Number of Participants Identified as Treatment Success After Completing Study Treatment in the Generic Estradiol Vaginal Cream, Estrace Vaginal Cream, and Vehicle Vaginal Cream Groups
Time Frame: Up to 9 months
|
The number of participants in the mITT Population that are identified as Treatment Success at the end of the treatment period evaluated on Day 8 ± 1 is presented.
A Treatment Success is defined as a score of 0 or 1 at Day 8 ± 1 for the symptom identified at baseline as the most bothersome.
This evaluation is to be based on participant self-assessed symptoms of vulvar and vaginal atrophy on a scale of 0 to 3 where 0 = none and 3 = severe.
The symptoms that were evaluated were vaginal dryness, vaginal/vulvar irritation/itching, dysuria, vaginal pain associated with sexual activity, and vaginal bleeding.
|
Up to 9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Study Director, Teva Pharmaceuticals USA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathological Conditions, Anatomical
- Vaginal Diseases
- Vaginitis
- Atrophic Vaginitis
- Atrophy
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Estradiol
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
Other Study ID Numbers
- 71436001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrophic Vaginitis
-
Fayoum UniversityRecruitingAtrophic Vaginitis | Postmenopausal Atrophic VaginitisEgypt
-
Amneal Pharmaceuticals, LLCCompletedAtrophic Vaginitis Due to MenopauseUnited States
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownAtrophic VaginitisChina
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAtrophic VaginitisUnited States
-
Alvogen Pine Brook LLCCompleted
-
Maire Mac BrideNational Center for Advancing Translational Sciences (NCATS)TerminatedAtrophic VaginitisUnited States
-
AGUNCO Obstetrics and Gynecology CentreCompletedAtrophic VaginitisItaly
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAtrophy | Vaginitis | Atrophic VaginitisUnited States, Canada
-
Izun Pharma LtdCompletedAtrophic VaginitisIsrael, United States
-
The Cleveland ClinicFoundation for Female Health AwarenessCompletedMenopause | Atrophic VaginitisUnited States
Clinical Trials on Generic Estradiol Vaginal Cream USP, 0.01%
-
Mylan Pharmaceuticals IncCompletedAtrophic VaginitisUnited States
-
University of Alabama at BirminghamRecruitingUrinary Incontinence | Sexual Dysfunction | Anal Incontinence | Obstetric; Injury Pelvic FloorUnited States
-
Children's Mercy Hospital Kansas CityUniversity of Missouri, Kansas CityCompleted
-
University of California, IrvineRecruitingRecurrent Urinary Tract Infection | HypoestrogenismUnited States
-
Stratpharma AGRecruitingGenitourinary Syndrome of MenopauseUnited States
-
University of California, San DiegoNYU Langone Health; American Urogynecologic SocietyCompletedRecurrent Urinary Tract InfectionUnited States
-
Medstar Health Research InstitutePfizerTerminatedMicroscopic HematuriaUnited States
-
Hospital Regional 1o de OctubreUniversidad Nacional Autonoma de Mexico; National Polytechnic Institute, Mexico and other collaboratorsCompletedMenopause | Genitourinary Syndrome of Menopause | Postmenopausal Disorder | Vagina AtrophyMexico
-
Wake Forest University Health SciencesRecruitingRecurrent Urinary Tract InfectionUnited States
-
TriHealth Inc.CompletedPelvic Organ Prolapse | Vaginal AtrophyUnited States